These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2117803)

  • 1. OKT3 therapy for hepatic allograft rejection: comparison of results in adults and children.
    Woodle ES; Thistlethwaite JR; Emond JC; Whitington PF; Black DD; Aran PP; Baker AL; Stuart FP; Broelsch CE
    Transplant Proc; 1990 Aug; 22(4):1765-6. PubMed ID: 2117803
    [No Abstract]   [Full Text] [Related]  

  • 2. Low serum OKT3 levels correlate with failure to prevent rejection in orthotopic liver transplant patients.
    McDiarmid SV; Millis M; Terashita G; Ament ME; Busuttil R; Terasaki P
    Transplant Proc; 1990 Aug; 22(4):1774-6. PubMed ID: 2117806
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of OKT3 in kidney, pancreas, and liver transplantation.
    D'Alessandro AM; Pirsch JD; Melzer JS; Sollinger HW; Kalayoglu M; Reed A; Knechtle SJ; Belzer FO
    Transplant Proc; 1990 Aug; 22(4):1748-9. PubMed ID: 2117796
    [No Abstract]   [Full Text] [Related]  

  • 4. Prolonged and repeated courses of OKT3 after liver transplantation.
    Colledan M; Gridelli B; Rossi G; Caccamo L; Gatti S; Bonara P; Fassati LR; Ferla G; Maggi U; Reggiani P
    Transplant Proc; 1990 Aug; 22(4):1769-71. PubMed ID: 2143859
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation.
    Steininger R; Mühlbacher F; Hamilton G; Längle F; Gnant M; Popow T; Sautner T; Götzinger P; Wamser P; Stockenhuber F
    Transplant Proc; 1991 Aug; 23(4):2269-71. PubMed ID: 1908154
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment with OKT3 and cyclosporine for acute allograft rejection.
    Schulak JA; Mayes JT; Hricik DE
    Transplant Proc; 1991 Aug; 23(4):2119-22. PubMed ID: 1908150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of cytomegalovirus reactivation after liver transplantation in cytomegalovirus immunoglobulin G antibody seropositive patients prior to transplantation.
    Cuervas-Mons V; Garrido A; Barrios C; Portero F; de la Loma A; Albillos A; Ardaiz J; Turrión VS; Mora NP; Herrera J
    Transplant Proc; 1990 Aug; 22(4):1798-9. PubMed ID: 2167530
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
    Macris MP; Frazier OH; Lammermeier D; Radovancevic B; Duncan JM
    J Heart Transplant; 1989; 8(4):281-7. PubMed ID: 2504894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orthoclone OKT3 treatment of acute renal allograft rejection in patients receiving maintenance cyclosporine therapy.
    Hirsch RL; Layton PC; Barnes LA; Kremer AB; Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):32-6. PubMed ID: 3105138
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunologic monitoring in OKT3-treated kidney graft recipients.
    Zlabinger GJ; Maurer D; Ulrich W; Meron G; Pohanka E; Kovarik J
    Transplant Proc; 1990 Aug; 22(4):1777-8. PubMed ID: 2117807
    [No Abstract]   [Full Text] [Related]  

  • 11. Pilot study on induction treatment with high-dose OKT3: preliminary observations in kidney transplantation.
    Welter HF; Illner WD; Schleibner S; Abendroth D; Hancke E; Groh J; Land W
    Transplant Proc; 1990 Oct; 22(5):2272. PubMed ID: 2120813
    [No Abstract]   [Full Text] [Related]  

  • 12. Orthoclone OKT3 monoclonal antibody reversal of hepatic and cardiac allograft rejection unresponsive to conventional immunosuppressive treatments.
    Kremer AB; Barnes L; Hirsch RL; Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):54-7. PubMed ID: 3105141
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of OKT3 for late acute rejection in liver transplantation.
    Samuel D; Gugenheim J; Canon C; Saliba F; Bismuth H
    Transplant Proc; 1990 Aug; 22(4):1767-8. PubMed ID: 2117804
    [No Abstract]   [Full Text] [Related]  

  • 14. OKT3 resistant rejection in liver transplant patients.
    Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical development of Orthoclone OKT3.
    Cosimi AB
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):7-16. PubMed ID: 3105142
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection.
    Cosimi AB; Cho SI; Delmonico FL; Kaplan MM; Rohrer RJ; Jenkins RL
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2431-3. PubMed ID: 3079083
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison between prophylactic use of OKT3 and cyclosporine in cadaveric renal transplantation.
    De Pauw L; Abramowicz D; Goldman M; Vereerstraeten P; Kinnaert P; Toussaint C
    Transplant Proc; 1990 Aug; 22(4):1759-60. PubMed ID: 2117800
    [No Abstract]   [Full Text] [Related]  

  • 18. Accelerated liver allograft rejection during prophylactic immunosuppression with OKT3.
    Sasaki AW; Lee RG; Porayko MK; Benner KG; Hennell KR; Wheeler LJ; Pinson CW
    Transplantation; 1993 Jan; 55(1):216-9. PubMed ID: 8420054
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of Orthoclone OKT3 as treatment of acute renal allograft rejection and as first-line therapy in kidney transplantation.
    Winde G; Dietl KH; Raidt H; Buchholz B; Lison AE; Bünte H
    Transplant Proc; 1988 Oct; 20(5 Suppl 6):87-9. PubMed ID: 3140453
    [No Abstract]   [Full Text] [Related]  

  • 20. OKT3 in severe early rejection: predictors for reversal in renal transplant recipients.
    Sumrani N; Delaney V; Rajpoot D; Tejani A; Butt K; Hong J
    Transplant Proc; 1990 Aug; 22(4):1750-2. PubMed ID: 2117797
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.